Advances in research on potential inhibitors of multiple myeloma

被引：3
|
作者：
Tang, Guoyuan [1 ]
Huang, Shan [2 ,3 ]
Luo, Ji [4 ,5 ]
Wu, Yingmiao [4 ,5 ]
Zheng, Shuai [4 ,5 ]
Tong, Rongsheng [1 ,6 ]
Zhong, Ling [4 ,5 ,7 ]
Shi, Jianyou [1 ,6 ]
机构：
[1] Chengdu Univ Tradit Chinese Med, State Key Lab Southwestern Chinese Med Resources, Chengdu 611137, Peoples R China
[2] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Canc Ctr, Chengdu 610072, Sichuan, Peoples R China
[3] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Chengdu 610072, Sichuan, Peoples R China
[4] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Ctr Med Genet, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu 610072, Sichuan, Peoples R China
[5] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Chengdu 610072, Sichuan, Peoples R China
[6] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Dept Pharm,Personalized Drug Therapy Key Lab Sichu, Chengdu 610072, Sichuan, Peoples R China
[7] Chinese Acad Sci, Chengdu Inst Biol, Chengdu 610041, Sichuan, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 262卷
基金：
中国国家自然科学基金; 中国博士后科学基金;
关键词：
Multiple myeloma; Drug resistance; Potential drugs; Structure-activity relationships; UBIQUITIN-PROTEASOME-SYSTEM; TOLL-LIKE RECEPTORS; TARGETED PROTEIN-DEGRADATION; DRUG-RESISTANCE; DEUBIQUITINATING ENZYMES; NEDD8-ACTIVATING ENZYME; CELL-PROLIFERATION; KINASE; SUPPRESSES; ACTIVATION;
D O I：
10.1016/j.ejmech.2023.115875
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Multiple myeloma (MM) is a common hematological malignancy. Although recent clinical applications of immunomodulatory drugs, proteasome inhibitors and CD38-targeting antibodies have significantly improved the outcome of MM patient with increased survival, the incidence of drug resistance and severe treatment-related complications is gradually on the rise. This review article summarizes the characteristics and clinical investigations of several MM drugs in clinical trials, including their structures, mechanisms of action, structure activity relationships, and clinical study progress. Furthermore, the application potentials of the drugs that have not yet entered clinical trials are also reviewed. The review also outlines the future directions of MM drug development.
引用
收藏
页数：19
相关论文
共 50 条
  • [41] Proteasome inhibitors in the treatment of multiple myeloma
    J J Shah
    R Z Orlowski
    Leukemia, 2009, 23 : 1964 - 1979
  • [42] Histone deacetylase inhibitors in multiple myeloma
    Deleu, Sarah
    Menu, Eline
    Van Valckenborgh, Els
    Van Camp, Ben
    Fraczek, Joanna
    Broek, Isabelle Vande
    Rogiers, Vera
    Vanderkerken, Karin
    HEMATOLOGY REPORTS, 2009, 1 (01) : 46 - 55
  • [43] Proteasom inhibitors in multiple myeloma: an update
    Malard, Florent
    Mohty, Mohamad
    HEMATOLOGIE, 2015, 21 (06): : 326 - 332
  • [44] The Role of JAK Inhibitors in Multiple Myeloma
    Ghermezi, Matthew
    Spektor, Tanya M.
    Berenson, James R.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (09) : 500 - 505
  • [45] Histone deacetylase inhibitors in multiple myeloma
    Pratt, Guy
    LANCET ONCOLOGY, 2013, 14 (11): : 1038 - 1039
  • [46] Proteasome inhibitors for the treatment of multiple myeloma
    Scalzulli, Emilia
    Grammatico, Sara
    Vozella, Federico
    Petrucci, Maria Teresa
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (04) : 375 - 386
  • [47] Novel proteasome inhibitors in multiple myeloma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2006, 6 (05): : 370 - 372
  • [48] The proteasome and proteasome inhibitors in multiple myeloma
    Sara Gandolfi
    Jacob P. Laubach
    Teru Hideshima
    Dharminder Chauhan
    Kenneth C. Anderson
    Paul G. Richardson
    Cancer and Metastasis Reviews, 2017, 36 : 561 - 584
  • [49] BRAF inhibitors in the therapy of multiple myeloma
    Kunze, A.
    Giesen, N.
    Raab, M-S
    ONKOLOGE, 2020, 26 (08): : 698 - 707
  • [50] Proteasome Inhibitors for the Treatment of Multiple Myeloma
    Ito, Shigeki
    CANCERS, 2020, 12 (02)
12345